End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.76 CNY | +0.45% | -8.80% | -1.01% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its low valuation, with P/E ratio at 10.78 and 7.78 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.01% | 3.63B | C | ||
+21.91% | 5.62B | C | ||
-11.63% | 4.38B | C- | ||
+1.25% | 2.05B | - | - | |
-1.82% | 1.52B | B+ | ||
-13.64% | 1.24B | B | ||
-6.39% | 931M | - | ||
-1.81% | 880M | - | D+ | |
-0.24% | 601M | - | - | |
-24.19% | 437M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002080 Stock
- Ratings Sinoma Science & Technology Co.,Ltd.